Price
1,120
+1.11%52W Range
Market Cap
₹1,12,698.21 Cr
Traded: ₹111.31 Cr (0.10%) 0.0x
Free Float: ₹7,697.29 Cr (1.45% of FF traded)
Volume · 60D trend
10.06 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Return | +12.0% | +17.0% | +22.0% | +25.0% | -- | Accelerating |
| Profit | +11.0% | +19.0% | +32.0% | -- | +5.0% | Stable |
| Sales | +11.0% | +12.0% | +16.0% | -- | +21.0% | Accelerating |
| ROE | +20.0% | +21.0% | +21.0% | -- | -- | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8,017 | 7,587 | 6,864 | 6,123 | 6,574 | 6,528 | 5,269 | 5,237 | 6,208 | 5,534 | 4,505 | 4,369 | 5,140 | 5,011 | 4,257 | 4,135 |
| Expenses | 6,088 | 5,033 | 5,048 | 4,107 | 4,485 | 4,402 | 3,882 | 3,776 | 4,124 | 3,903 | 3,403 | 3,223 | 3,634 | 3,755 | 3,301 | 3,319 |
| Operating Profit | 1,929 | 2,554 | 1,816 | 2,016 | 2,088 | 2,126 | 1,388 | 1,461 | 2,084 | 1,630 | 1,102 | 1,146 | 1,505 | 1,256 | 956 | 815 |
| OPM % | 24.0% | 34.0% | 26.0% | 33.0% | 32.0% | 33.0% | 26.0% | 28.0% | 34.0% | 29.0% | 24.0% | 26.0% | 29.0% | 25.0% | 22.0% | 20.0% |
| Other Income | 88 | -263 | 26 | 75 | 155 | -139 | 57 | 68 | 63 | 160 | 60 | 53 | 21 | -566 | 39 | 50 |
| Interest | 156 | 123 | 130 | 101 | 85 | 77 | 32 | 25 | 32 | 35 | 20 | 9 | 18 | 28 | 33 | 35 |
| Depreciation | 555 | 508 | 360 | 302 | 238 | 238 | 229 | 234 | 215 | 205 | 195 | 184 | 180 | 179 | 182 | 182 |
| Profit Before Tax | 1,307 | 1,660 | 1,353 | 1,687 | 1,921 | 1,672 | 1,184 | 1,271 | 1,900 | 1,550 | 947 | 1,006 | 1,328 | 484 | 780 | 648 |
| Tax % | 27.0% | 19.0% | 29.0% | 27.0% | 23.0% | 25.0% | 15.0% | 29.0% | 23.0% | 21.0% | 23.0% | 22.0% | 16.0% | 28.0% | 25.0% | 21.0% |
| Net Profit | 990 | 1,341 | 1,023 | 1,239 | 1,521 | 1,244 | 1,026 | 920 | 1,482 | 1,246 | 790 | 803 | 1,134 | 358 | 631 | 526 |
| Exceptional Items | -18 | -398 | -85 | -34 | 0 | -220 | 0 | 0 | 0 | 3 | 22 | -1 | -15 | -604 | 0 | 6 |
| EPS (Rs) | 9.4 | 12.7 | 10.4 | 12.5 | 14.6 | 11.6 | 10.2 | 9.1 | 14.1 | 11.8 | 7.8 | 7.9 | 10.7 | 2.9 | 6.2 | 5.2 |
| Sales Growth (YoY) | 21.9% | 16.2% | 30.3% | 16.9% | 5.9% | 18.0% | 17.0% | 19.9% | 20.8% | 10.4% | 5.8% | 5.7% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 5.7% | 10.5% | 12.1% | -6.9% | 0.7% | 23.9% | 0.6% | -15.6% | 12.2% | 22.8% | 3.1% | -15.0% | 2.6% | 17.7% | 3.0% | -- |
| OP Growth (YoY) | -7.6% | 20.1% | 30.8% | 38.0% | 0.2% | 30.4% | 26.0% | 27.5% | 38.5% | 29.8% | 15.3% | 40.6% | -- | -- | -- | -- |
| OP Growth (QoQ) | -24.5% | 40.6% | -9.9% | -3.4% | -1.8% | 53.2% | -5.0% | -29.9% | 27.9% | 47.9% | -3.8% | -23.9% | 19.8% | 31.4% | 17.3% | -- |
| Profit Growth (YoY) | -- | 22.0% | 8.0% | 41.0% | 3.0% | 6.0% | 33.0% | 14.0% | 30.0% | 95.0% | 23.0% | 55.0% | 107.0% | 48.0% | 23.0% | -19.0% |
| EPS Growth (YoY) | -35.4% | 8.7% | 1.9% | 38.1% | 3.3% | -0.9% | 30.4% | 14.5% | 31.4% | 301.0% | 26.8% | 53.3% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -25.5% | 22.1% | -17.2% | -14.2% | 25.3% | 14.4% | 12.3% | -35.8% | 20.1% | 50.6% | -1.4% | -26.4% | 266.6% | -52.4% | 19.2% | -- |
| OP Margin | 24.1% | 33.7% | 26.5% | 32.9% | 31.8% | 32.6% | 26.3% | 27.9% | 33.6% | 29.4% | 24.5% | 26.2% | 29.3% | 25.1% | 22.5% | 19.7% |
| Net Margin | 12.3% | 17.7% | 14.9% | 20.2% | 23.1% | 19.1% | 19.5% | 17.6% | 23.9% | 22.5% | 17.5% | 18.4% | 22.1% | 7.1% | 14.8% | 12.7% |
| Material Cost % | -- | 26.1% | 26.8% | 27.6% | 27.2% | 26.0% | 30.1% | 28.1% | 25.6% | 29.1% | 32.6% | 33.7% | 32.6% | 33.9% | 35.5% | 38.6% |
| Employee Cost % | -- | 16.3% | 16.6% | 16.9% | 15.3% | 14.9% | 18.0% | 16.8% | 14.2% | 15.1% | 18.1% | 17.2% | 14.2% | 14.4% | 16.2% | 16.3% |
| P/S | 3.94 | 4.15 | 3.82 | 3.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 24.92 | 22.34 | 20.19 | 18.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 4.16 | 4.45 | 3.94 | 3.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Investor Presentation
ESG Rating
Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity.
Transcript of the post results earnings call held on August 11, 2026
The management of the Company will meet the investors in Singapore and Hong Kong between August 24, 2026, to August 26, 2026, in the form of a Non-Deal Roadshow (NDR).
Update on Investor Conference
Newspaper cutting with regard to publication of unaudited financial results for the quarter ended on June 30, 2026, in Financial Express on August 12, 2026.
Regulation 44(3) disclosure of AGM 2026
Change in Directors
Audio Link of the Investor Call held on August 11 2026
Reporting of violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015
Press Release
Investor Presentation
Unaudited financial results for the quarter ended on June 30, 2026
Press Release
Unaudited financial results for the quarter ended on June 30, 2026
Scrutinizer''s report
Outcome of AGM
Zydus launches REVAHALE, India''s first once-daily nebulised LAMA for COPD.
The Company is going to participate in Motilal Oswal 22nd Annual Global Investor Conference, 2026 on August 18, 2026.
Disruption of operations due to heavy rain and water logging
Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR.
Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve unaudited financial results ....
Reply to the clarification sought from the company
The Exchange has sought Clarification from Zydus Lifesciences Ltd with reference to the media report appearing on https://www.ndtvprofit.com dated July 14, 2026, (Link: https://www.ndtvprofit.com/business/delhi-high-court-temporarily-restricts-supply-of-zydus-cancer-drug-ikra-in-abbvie-patent-dispute-11764992) ....
The newspaper cutting dated July 11, 2026, with regard to Notice of 31st Annual General Meeting of the Company published in the Financial Express.
Business Responsibility and Sustainability Report for the financial year ended on March 31, 2026
Integrated Annual Report for the FY 2025-26
Notice of Annual General Meeting
The newspaper advertisement published in the Financial Express English and Gujarati edition with regard to the Notice to the shareholders for claiming their shares which are proposed to ....
Certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended on June 30, 2026
Newspaper cutting dated July 4, 2026 with regard to Notice and information of 31st Annual General Meeting of the Company published in the Financial Express.
Press Release
Update on acquisition of API business
Joint Venture in Sri Lanka
Intimation of Trading Window Closure
Disclosures under SEBI (Prohibition of Insider Trading) Regulations, 2015
Extinguishment Certificate
Post Buyback Public Advertisement
Completion of merger of Assertio Holdings Inc.
Zydus announces the successful completion of acquisition of Assertio Holdings.
Newspaper publication of notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati Editions, both on June 11, 2026.
Intimation of drop in GST demand
Revised Letter of Offer
Letter of Offer
Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA.
Newspaper publication of addendum to public announcement
Addendum to the Public Announcement for the Buyback of equity shares
Update
Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015
Annual Reports
15Credit Ratings
6Concalls
50Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025Jun 2025
30 Jun 2025May 2025
31 May 2025Mar 2025
31 Mar 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Sep 2023
30 Sept 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Sep 2021
30 Sept 2021Aug 2021
31 Aug 2021May 2021
31 May 2021Feb 2021
28 Feb 2021Jan 2021
31 Jan 2021Oct 2020
31 Oct 2020Aug 2020
31 Aug 2020Aug 2020
31 Aug 2020Jun 2020
30 Jun 2020Mar 2020
31 Mar 2020Feb 2020
29 Feb 2020Feb 2020
29 Feb 2020Nov 2019
30 Nov 2019Jul 2019
31 Jul 2019Jun 2019
30 Jun 2019Jan 2019
31 Jan 2019Jan 2019
31 Jan 2019Jun 2018
30 Jun 2018May 2018
31 May 2018Nov 2017
30 Nov 2017Sep 2017
30 Sept 2017Jun 2017
30 Jun 2017Mar 2017
31 Mar 2017Feb 2017
28 Feb 2017Jan 2017
31 Jan 2017Nov 2016
30 Nov 2016May 2016
31 May 2016Held by ETFs
42 ETFs hold zyduslife · sorted by weight
Held by Mutual Funds
89 schemes hold zyduslife · sorted by weight